论文部分内容阅读
为研究阿米卡星（ＡＭＫ）在不同年龄呼吸系感染病人中的药物动力学特性，采用荧光偏振免疫法（ＦＰＩＡ）测定病人血中ＡＭＫ浓度，根据药－时数据求出药物动力学参数。结果表明，ＡＭＫ在青年病人组和老年病人组中的末端相消除半衰期分别为３．０２±０．６３ｈ和４．４８±１．３９ｈ，老年病人组明显长于青年病人组（Ｐ＜０．０５）。药物峰浓度分别为３８．７０±７．５１ｍｇ／Ｌ和４０．０６±５．３０ｍｇ／Ｌ，两组间无差异。研究证明，在肾功正常的条件下，年龄因素是影响ＡＭＫ消除半衰期的重要因素之一，但不影响药物峰浓度及其它药物动力学参数。因此，老年病人应用ＡＭＫ时应进行血药浓度监测
In order to study the pharmacokinetics of amikacin (AMK) in patients with respiratory infection at different ages, AMK concentrations in patients’ blood were measured by fluorescence polarization immunoassay (FPIA). Pharmacokinetic parameters were calculated based on the drug-time data. The results showed that the half-life of AMK was 3.02 ± 0.63 h and 4.48 ± 1.39 h in young patients and elderly patients, respectively, which was significantly longer in elderly patients than in young patients (P <0.05) ). Drug peak concentrations were 38.70 ± 7.51mg / L and 40.06 ± 5.30mg / L, no difference between the two groups. Studies have shown that in the normal conditions of kidney function, age factor is one of the important factors that affect the elimination half-life of AMK, but does not affect the drug peak concentration and other pharmacokinetic parameters. Therefore, elderly patients should be monitored when using AMK blood concentration